A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer

[1]  J. McCubrey,et al.  Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs , 2009, The Prostate.

[2]  P. Morris,et al.  Microtubule Active Agents: Beyond the Taxane Frontier , 2008, Clinical Cancer Research.

[3]  H. Hsieh,et al.  Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. , 2008, Journal of medicinal chemistry.

[4]  M. Stillman,et al.  Chemotherapy-induced peripheral neuropathy. , 2005, Oncology nursing forum.

[5]  H. Hsieh,et al.  4- and 5-aroylindoles as novel classes of potent antitubulin agents. , 2007, Journal of medicinal chemistry.

[6]  S. Cole,et al.  Mutational Analysis of a Highly Conserved Proline Residue in MRP1, MRP2, and MRP3 Reveals a Partially Conserved Function , 2007, Drug Metabolism and Disposition.

[7]  G. Szakács,et al.  Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance. , 2006, Journal of Medicinal Chemistry.

[8]  P. Houghton,et al.  In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer Models , 2005, Clinical Cancer Research.

[9]  T. Beckers,et al.  Synthesis and cytotoxic activity of 2-acyl-1H-indole-4,7-diones on human cancer cell lines. , 2005, European journal of medicinal chemistry.

[10]  M. Kavallaris,et al.  Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. , 2005, Current pharmaceutical design.

[11]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[12]  H. Hsieh,et al.  BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo , 2004, Cancer Research.

[13]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[14]  T. Fojo,et al.  The role of ABC transporters in clinical practice. , 2003, The oncologist.

[15]  M. Bissery,et al.  The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation , 2003, Investigational New Drugs.

[16]  G. Firestone,et al.  Plant-derived 3,3′-Diindolylmethane Is a Strong Androgen Antagonist in Human Prostate Cancer Cells* , 2003, Journal of Biological Chemistry.

[17]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[18]  U. Vanhoefer,et al.  2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. , 2002, Cancer research.

[19]  T. Beckers,et al.  Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. , 2001, Journal of medicinal chemistry.

[20]  T. Chou,et al.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Lee,et al.  BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Fares,et al.  Induction of apoptosis in MCF-7 cells by indole-3-carbinol is independent of p53 and bax. , 1999, Anticancer research.

[23]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Savin,et al.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Mayumi,et al.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly. , 1998, The Biochemical journal.

[26]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[27]  C. Croce,et al.  Bcl2 is the guardian of microtubule integrity. , 1997, Cancer research.

[28]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[29]  T. Tsuruo,et al.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. , 1986, Japanese journal of cancer research : Gann.

[30]  M L Mendelsohn,et al.  Analysis of tumor growth curves. , 1968, Journal of the National Cancer Institute.

[31]  C. Mitsiades,et al.  Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. , 2005, Blood.

[32]  S Seeber,et al.  D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. , 2001, Cancer research.

[33]  G. Rennert,et al.  Dietary indole derivatives induce apoptosis in human breast cancer cells. , 1998, Advances in experimental medicine and biology.

[34]  E. Hamel.  Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. , 1992, Pharmacology & therapeutics.